EP2432489A4 - Variants du peptide natriurétique de type c - Google Patents

Variants du peptide natriurétique de type c

Info

Publication number
EP2432489A4
EP2432489A4 EP10778389A EP10778389A EP2432489A4 EP 2432489 A4 EP2432489 A4 EP 2432489A4 EP 10778389 A EP10778389 A EP 10778389A EP 10778389 A EP10778389 A EP 10778389A EP 2432489 A4 EP2432489 A4 EP 2432489A4
Authority
EP
European Patent Office
Prior art keywords
variants
natriuretic peptide
type natriuretic
type
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10778389A
Other languages
German (de)
English (en)
Other versions
EP2432489B1 (fr
EP2432489A2 (fr
Inventor
Daniel J Wendt
Mika Aoyagi-Scharber
Shinong Long
Michel Claude Vellard
Sianna Castillo
Augustus O Okhamafe
Christopher P Price
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43124672&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2432489(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP21211450.8A priority Critical patent/EP4029512A1/fr
Priority to EP16192229.9A priority patent/EP3175863B1/fr
Priority to PL16192229T priority patent/PL3175863T3/pl
Priority to DK16192229.9T priority patent/DK3175863T3/da
Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc
Publication of EP2432489A2 publication Critical patent/EP2432489A2/fr
Publication of EP2432489A4 publication Critical patent/EP2432489A4/fr
Publication of EP2432489B1 publication Critical patent/EP2432489B1/fr
Application granted granted Critical
Priority to HRP20161739TT priority patent/HRP20161739T1/hr
Priority to HUS2200004C priority patent/HUS2200004I1/hu
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP10778389.6A 2009-05-20 2010-05-20 Variants du peptide natriurétique de type c Active EP2432489B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP21211450.8A EP4029512A1 (fr) 2009-05-20 2010-05-20 Variantes du peptide natriurétique de type c
EP16192229.9A EP3175863B1 (fr) 2009-05-20 2010-05-20 Variantes du peptide natriurétique de type c
PL16192229T PL3175863T3 (pl) 2009-05-20 2010-05-20 Warianty peptydu natriuretycznego typu C
DK16192229.9T DK3175863T3 (da) 2009-05-20 2010-05-20 Varianter af c-type natriuretisk peptid
HRP20161739TT HRP20161739T1 (hr) 2009-05-20 2016-12-19 VARIJANTE NATRIURETIČNOG PEPTIDA C-tipa
HUS2200004C HUS2200004I1 (hu) 2009-05-20 2022-01-20 A C-típusú nátriuretikus peptid variánsai

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18011209P 2009-05-20 2009-05-20
US25456309P 2009-10-23 2009-10-23
PCT/US2010/035586 WO2010135541A2 (fr) 2009-05-20 2010-05-20 Variants du peptide natriurétique de type c

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP16192229.9A Division EP3175863B1 (fr) 2009-05-20 2010-05-20 Variantes du peptide natriurétique de type c
EP21211450.8A Division EP4029512A1 (fr) 2009-05-20 2010-05-20 Variantes du peptide natriurétique de type c

Publications (3)

Publication Number Publication Date
EP2432489A2 EP2432489A2 (fr) 2012-03-28
EP2432489A4 true EP2432489A4 (fr) 2013-04-03
EP2432489B1 EP2432489B1 (fr) 2016-10-05

Family

ID=43124672

Family Applications (3)

Application Number Title Priority Date Filing Date
EP16192229.9A Active EP3175863B1 (fr) 2009-05-20 2010-05-20 Variantes du peptide natriurétique de type c
EP21211450.8A Pending EP4029512A1 (fr) 2009-05-20 2010-05-20 Variantes du peptide natriurétique de type c
EP10778389.6A Active EP2432489B1 (fr) 2009-05-20 2010-05-20 Variants du peptide natriurétique de type c

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP16192229.9A Active EP3175863B1 (fr) 2009-05-20 2010-05-20 Variantes du peptide natriurétique de type c
EP21211450.8A Pending EP4029512A1 (fr) 2009-05-20 2010-05-20 Variantes du peptide natriurétique de type c

Country Status (27)

Country Link
US (6) US8198242B2 (fr)
EP (3) EP3175863B1 (fr)
JP (1) JP5718909B2 (fr)
KR (5) KR102225470B1 (fr)
CN (1) CN102481330B (fr)
AR (1) AR078044A1 (fr)
AU (1) AU2010249802B2 (fr)
BR (2) BRPI1012783B1 (fr)
CA (1) CA2758581C (fr)
CL (1) CL2011002430A1 (fr)
DK (2) DK3175863T3 (fr)
ES (2) ES2904360T3 (fr)
FI (1) FIC20220003I1 (fr)
FR (1) FR22C1004I2 (fr)
HK (1) HK1168279A1 (fr)
HR (2) HRP20220057T1 (fr)
HU (3) HUE057174T2 (fr)
IL (1) IL215287A (fr)
MX (1) MX2011012277A (fr)
NO (1) NO2022003I1 (fr)
PE (1) PE20120792A1 (fr)
PL (2) PL2432489T3 (fr)
PT (2) PT3175863T (fr)
RU (1) RU2573911C2 (fr)
TW (1) TWI471137B (fr)
WO (1) WO2010135541A2 (fr)
ZA (1) ZA201107087B (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3404102B1 (fr) 2004-04-21 2021-08-11 Alexion Pharmaceuticals, Inc. Conjugués d'administration d'os et procédé pour les utiliser pour cibler des protéines sur l'os
EP3175863B1 (fr) * 2009-05-20 2021-12-01 BioMarin Pharmaceutical Inc. Variantes du peptide natriurétique de type c
KR101226165B1 (ko) 2009-07-23 2013-01-24 가부시키가이샤 이기스 피부 외용제 조성물
KR101229546B1 (ko) * 2009-08-27 2013-02-05 쿄고 엔도 비염 치료제
US9988620B2 (en) 2010-04-30 2018-06-05 Alexion Pharmaceuticals, Inc. Methods, compositions, and kits for the treatment of matrix mineralization disorders
EP2658979B1 (fr) * 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Compositions contenant des peptides natriurétiques et leurs méthodes d'utilisation
US20120277155A1 (en) 2011-02-25 2012-11-01 Medtronic, Inc. Therapy for kidney disease and/or heart failure
AU2012287226A1 (en) * 2011-07-27 2014-02-20 Capricor Therapeutics, Inc. Natriuretic peptide compositions and methods of preparation
WO2013033675A1 (fr) * 2011-09-02 2013-03-07 Medtronic, Inc. Compositions de peptides natriurétiques chimériques et procédés de préparation
WO2013058833A1 (fr) 2011-10-19 2013-04-25 Enobia Canada Limited Partnership Compositions comprenant une phosphatase alcaline et/ou un peptide natriurétique et leurs procédés d'utilisation
EP2794646A4 (fr) * 2011-12-23 2015-12-09 Mayo Foundation Évaluation des modifications structurelles rénales et évolutions de celles-ci
EP2853273A4 (fr) * 2012-04-25 2016-01-13 Daiichi Sankyo Co Ltd Accélérateur de réparation osseuse
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
EP2908861A4 (fr) * 2012-10-19 2016-04-20 Univ Cornell Lubrifiants biomimétiques de la couche limite pour cartilage articulaire
CA2882881A1 (fr) * 2013-03-10 2014-09-18 National University Corporation Nagoya University Agent therapeutique pour maladie osseuse systemique et utilisation associee
CN103159847B (zh) * 2013-04-12 2014-05-28 叶亮 一种利钠肽及其基因与用途
AU2015206515B2 (en) 2014-01-15 2019-12-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cartilage targeting agents and their use
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
EP3226891A1 (fr) 2014-12-05 2017-10-11 Alexion Pharmaceuticals, Inc. Traitement de crise avec une phosphatase alcaline recombinée
WO2016110577A1 (fr) * 2015-01-09 2016-07-14 Ascendis Pharma A/S Promédicaments de cnp
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
DK3328416T5 (da) 2015-07-30 2024-10-07 Biomarin Pharm Inc Anvendelse af natriuretske peptidvarianter af c-typen til behandling af skeletdysplasi
EP3330280A4 (fr) * 2015-07-31 2019-06-12 Igisu Co., Ltd. Peptide cyclique cnp et médicament, préparation à usage externe et produit cosmétique, contenant tous ledit peptide cyclique
JP6993961B2 (ja) 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造
WO2017058822A1 (fr) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identification de régimes posologiques efficaces pour une thérapie de l'hypophosphatasie de remplacement de l'enzyme phosphatase alcaline non spécifique à des tissus (tnsalp)
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
KR20180088459A (ko) * 2015-12-08 2018-08-03 바이오마린 파머수티컬 인크. 골관절염을 치료하기 위한 c-형 나트륨이뇨 펩타이드 변이체의 용도
AU2017205273C1 (en) 2016-01-08 2022-12-01 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with reduced side-effects
NZ743487A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
EP3400022A1 (fr) * 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Agonistes de cnp à libération contrôlée avec faible activité npr-b initiale
RS63793B1 (sr) * 2016-01-08 2022-12-30 Ascendis Pharma Growth Disorders As Cnp prolekovi kod kojih je nosač povezan sa cikličnom komponentom
JP7051686B2 (ja) * 2016-01-08 2022-04-11 アセンディス ファーマ グロース ディスオーダーズ エー／エス 大型のキャリアー部分を有するｃｎｐプロドラッグ
IL259829B2 (en) * 2016-01-08 2023-03-01 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low npr–c binding
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
KR20220162816A (ko) 2016-04-01 2022-12-08 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
WO2017173395A1 (fr) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Méthodes de traitement de l'hypophosphatasie chez les adolescents et les adultes
WO2017214130A1 (fr) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Impact du métal sur la production des phosphatases alcalines
WO2018011266A1 (fr) * 2016-07-13 2018-01-18 Ascendis Pharma A/S Procédé de conjugaison pour promédicaments liés à un support
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
SG11201901534VA (en) * 2016-09-29 2019-03-28 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
US20180194824A1 (en) 2016-12-14 2018-07-12 University Of Iowa Research Foundation Musclin peptides and methods of use thereof
EP3574913A4 (fr) * 2017-01-24 2020-07-22 Daiichi Sankyo Company, Limited Agent thérapeutique pour la petite taille
SI3592393T1 (sl) 2017-03-10 2022-04-29 Quiapeg Pharmaceuticals Ab Sprostljivi konjugati
CN110719786A (zh) 2017-03-31 2020-01-21 阿雷克森制药公司 用于治疗成人和青少年的低磷酸酯酶症(hpp)的方法
WO2019190752A1 (fr) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Production de glycoprotéines
EP3553082A1 (fr) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Anticorps greffés de peptide natriurétique du cerveau
EP3553079A1 (fr) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Anticorps greffés de peptide natriurétique de type c
EP3553081A1 (fr) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft Anticorps greffés de peptide natriurétique auriculaire
BR112021004689A2 (pt) 2018-09-12 2021-06-08 Quiapeg Pharmaceuticals Ab conjugados glp-1 liberáveis
US20220118053A1 (en) 2019-02-11 2022-04-21 Ascendis Pharma Growth Disorders A/S Dry Pharmaceutical Formulations of CNP Conjugates
MA56180A (fr) 2019-06-12 2022-04-20 Novartis Ag Anticorps du récepteur 1 du peptide natriurétique et procédés d'utilisation
CN114423447A (zh) * 2019-08-12 2022-04-29 生物马林药物股份有限公司 用于延释组合物的疏水性肽盐
CN114616242A (zh) 2019-09-16 2022-06-10 生物马林药物股份有限公司 Cnp变体和其共轭物
KR20230024352A (ko) * 2020-06-12 2023-02-20 파마인 코포레이션 C형 나트륨이뇨 펩타이드 및 이의 급성 폐 손상의 치료에서의 방법
WO2022115563A1 (fr) * 2020-11-25 2022-06-02 Prolynx Llc Conjugués d'hydrogel à libération prolongée de peptides c-natriurétiques
CA3173631A1 (fr) 2021-02-12 2022-08-18 Walter C. Voegtli Polypeptides de phosphatase alcaline et leurs methodes d'utilisation
RU2763661C2 (ru) * 2021-03-31 2021-12-30 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ терапии и профилактики прогрессирования хронической почечной недостаточности
EP4366758A1 (fr) 2021-07-09 2024-05-15 BioMarin Pharmaceutical Inc. Variants de peptides natriurétiques de type c pour traiter la dysplasie squelettique chez les enfants
TW202334188A (zh) * 2021-12-07 2023-09-01 美商拜奧馬林製藥公司 Ｃｎｐ療法
AU2022413318A1 (en) * 2021-12-13 2024-05-16 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
WO2023117855A1 (fr) * 2021-12-20 2023-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'un analogue de peptide natriurétique de type c pour le traitement de la réparation osseuse liée au fgfr et de la détérioration de l'ostéogenèse
EP4490300A1 (fr) * 2022-03-11 2025-01-15 Avirmax Biopharma Inc. Compositions et procédés d'expression d'agents thérapeutiques
WO2023227505A1 (fr) 2022-05-23 2023-11-30 Ascendis Pharma Growth Disorders A/S Formulations pharmaceutiques liquides de composés cnp
KR20240172760A (ko) 2022-11-02 2024-12-10 노보 노르디스크 에이/에스 Cnp 화합물
WO2024104922A1 (fr) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Procédé d'amélioration de la fonction musculaire squelettique
WO2024128729A1 (fr) * 2022-12-12 2024-06-20 주식회사 엘지생활건강 Composition cosmétique pour l'amélioration de la peau
WO2024194300A1 (fr) 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Méthode de traitement d'une déformation thoraco-lombaire chez un sujet humain atteint d'achondroplasie
WO2024254405A2 (fr) 2023-06-07 2024-12-12 Biomarin Pharmaceutical Inc. Criblage à haut débit pour variants génétiques associés à une petite taille

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0497368A1 (fr) * 1991-01-31 1992-08-05 Suntory Limited Peptides analogues de CNP et leur utilisation
US20080194682A1 (en) * 2001-03-20 2008-08-14 Prochon Biotech Ltd. Method and composition for treatment of skeletal dysplasias

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE121102T1 (de) 1990-04-20 1995-04-15 Hisayuki Matsuo Neue im schwein vorkommende physiologisch aktive peptide.
JP2930380B2 (ja) 1990-07-13 1999-08-03 壽之 松尾 ブタ由来新規生理活性ペプチド（ｃｎｐ―５３）
JP3026351B2 (ja) 1990-07-13 2000-03-27 壽之 松尾 ブタｃｎｐ遺伝子及び前駆体蛋白
JP3026354B2 (ja) 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
AU6360394A (en) 1993-03-03 1994-09-26 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
US5846932A (en) 1993-11-12 1998-12-08 Genentech, Inc. Receptor specific atrial natriuretic peptides
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
CZ295468B6 (cs) 1996-04-12 2005-08-17 Warner-Lambert Company Polycyklické sloučeniny
US6329375B1 (en) 1997-08-05 2001-12-11 Sugen, Inc. Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
US6136040A (en) 1998-03-05 2000-10-24 Washington University Animal model with disrupted FGF-9 gene
IL125958A0 (en) * 1998-08-27 1999-04-11 Yeda Res & Dev Animal model for fibroblast growth factor receptor associated chondrodysplasia
WO2000061631A1 (fr) 1999-04-12 2000-10-19 Astrazeneca Ab Antagonistes de pentapeptides modifies du recepteur de la clairance des peptides natriuretiques auriculaires
US6849714B1 (en) * 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
DE60137525D1 (de) 2000-10-16 2009-03-12 Chugai Pharmaceutical Co Ltd Peg-modifiziertes erythropoietin
JP2002178279A (ja) 2000-12-12 2002-06-25 Ulvac Japan Ltd 基板搬送方法
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
BRPI0203172B8 (pt) * 2001-09-28 2021-05-25 Nakao Kazuwa composição farmacêutica para acondroplasia
US20040077537A1 (en) * 2002-03-18 2004-04-22 Schreiner George F. Method for treating congestive heart failure
US6861236B2 (en) * 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
US20040152769A1 (en) 2002-11-09 2004-08-05 Ekwuribe Nnochiri Nkem Modified carbamate-containing prodrugs and methods of synthesizing same
BR0316560A (pt) 2002-11-26 2005-10-04 Nobex Corp Conjugado de composto natriurético, formulação farmacêutica, método de tratar uma condição, método de preparação do conjugado de composto natriurético, conjugado de peptìdeo pró-polinatriurético modificado, análogo de peptìdeo natriurético, análogo de hbnp, composto, e, método de preparar um composto
US7648962B2 (en) 2002-11-26 2010-01-19 Biocon Limited Natriuretic compounds, conjugates, and uses thereof
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004030342D1 (de) * 2003-06-17 2011-01-13 Otago Innovation Ltd Beurteilung des skelettwachstums unter verwendung von messungen von nt-cnp-peptiden
EP1525890A1 (fr) 2003-10-02 2005-04-27 Complex Biosystems GmbH Complexes protéine-protéophore
ES2741524T3 (es) 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Profármaco polimérico con un enlazador autoinmolador
JP4825667B2 (ja) * 2004-03-31 2011-11-30 一和 中尾 関節炎症治療剤又は予防剤
EP3620530A1 (fr) * 2004-03-31 2020-03-11 Kazuwa Nakao Composition pour augmenter la hauteur du corps
JP2005292718A (ja) 2004-04-05 2005-10-20 Furukawa Electric Co Ltd:The 光導波路、光導波路モジュールおよび光導波路の作成方法
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
EP1773867B1 (fr) * 2004-07-15 2011-01-19 The University Of Queensland Composes proteiniques et leurs utilisations
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CA2689492A1 (fr) 2007-06-06 2008-12-18 Boehringer Ingelheim International Gmbh Proteines de fusion natriuretiques
DK2765139T3 (en) * 2007-07-20 2017-07-31 Mayo Foundation NATURURETIC POLYPEPTIDES
AU2008297898A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of C-type natriuretic peptide, alone or incombination with neuropeptide AF, as a therapeutic agent
AU2008326327A1 (en) 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptide
US20090163421A1 (en) 2007-12-19 2009-06-25 Ekr Therapeutics, Inc. Room Temperature Stable, Lyophilized Natriuretic Peptide Formulations
PT2237799T (pt) 2008-02-01 2019-07-05 Ascendis Pharma As Pró-fármaco compreendendo um ligador autoclivável
JP5524049B2 (ja) * 2008-05-23 2014-06-18 第一三共株式会社 目的ペプチドの血漿中半減期延長作用を有するペプチド
EP2334334A1 (fr) 2008-09-19 2011-06-22 Nektar Therapeutics Conjugués polymères de peptides de nesiritide
EP3175863B1 (fr) 2009-05-20 2021-12-01 BioMarin Pharmaceutical Inc. Variantes du peptide natriurétique de type c
DK2525830T3 (en) 2010-01-22 2016-08-15 Ascendis Pharma As DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0497368A1 (fr) * 1991-01-31 1992-08-05 Suntory Limited Peptides analogues de CNP et leur utilisation
US20080194682A1 (en) * 2001-03-20 2008-08-14 Prochon Biotech Ltd. Method and composition for treatment of skeletal dysplasias

Also Published As

Publication number Publication date
HRP20220057T1 (hr) 2022-04-15
PL2432489T3 (pl) 2017-05-31
BR122019026832B1 (pt) 2021-08-24
US20120316114A1 (en) 2012-12-13
US20100297021A1 (en) 2010-11-25
DK2432489T3 (en) 2017-01-16
CA2758581A1 (fr) 2010-11-25
PT2432489T (pt) 2016-12-07
AR078044A1 (es) 2011-10-12
PE20120792A1 (es) 2012-07-27
KR20180021233A (ko) 2018-02-28
TWI471137B (zh) 2015-02-01
US8198242B2 (en) 2012-06-12
AU2010249802B2 (en) 2017-06-08
USRE48267E1 (en) 2020-10-20
IL215287A0 (en) 2011-11-30
WO2010135541A2 (fr) 2010-11-25
BRPI1012783A2 (pt) 2018-01-16
PT3175863T (pt) 2022-01-20
HK1168279A1 (zh) 2012-12-28
KR20120034660A (ko) 2012-04-12
KR20190119179A (ko) 2019-10-21
TW201100092A (en) 2011-01-01
USRE46707E1 (en) 2018-02-13
PL3175863T3 (pl) 2022-03-21
CL2011002430A1 (es) 2012-02-17
KR102033680B1 (ko) 2019-10-18
EP2432489B1 (fr) 2016-10-05
JP5718909B2 (ja) 2015-05-13
US20170051033A1 (en) 2017-02-23
US8598121B2 (en) 2013-12-03
FIC20220003I1 (fi) 2022-01-19
HUS2200004I1 (hu) 2022-05-28
AU2010249802A1 (en) 2011-10-13
KR102225470B1 (ko) 2021-03-10
RU2011152007A (ru) 2013-06-27
US20160256553A1 (en) 2016-09-08
DK3175863T3 (da) 2022-02-07
EP3175863B1 (fr) 2021-12-01
HRP20161739T1 (hr) 2017-03-10
FR22C1004I2 (fr) 2023-01-13
KR101831923B1 (ko) 2018-02-26
CN102481330B (zh) 2014-12-10
JP2012527244A (ja) 2012-11-08
RU2573911C2 (ru) 2016-01-27
EP3175863A1 (fr) 2017-06-07
MX2011012277A (es) 2011-12-12
HUE032582T2 (en) 2017-09-28
NO2022003I1 (no) 2024-08-05
EP2432489A2 (fr) 2012-03-28
IL215287A (en) 2015-04-30
ES2608457T3 (es) 2017-04-11
HUE057174T2 (hu) 2022-04-28
ES2904360T3 (es) 2022-04-04
BRPI1012783B1 (pt) 2021-09-21
WO2010135541A3 (fr) 2011-01-20
CN102481330A (zh) 2012-05-30
ZA201107087B (en) 2012-12-27
CA2758581C (fr) 2022-06-14
KR20230142644A (ko) 2023-10-11
FR22C1004I1 (fr) 2022-03-11
KR20210027537A (ko) 2021-03-10
EP4029512A1 (fr) 2022-07-20

Similar Documents

Publication Publication Date Title
HUS2200004I1 (hu) A C-típusú nátriuretikus peptid variánsai
TWI367213B (en) Variants of c-type natriuretic peptide
HK1170941A1 (en) Oxyntomodulin peptide analogue
HK1170943A1 (en) Oxyntomodulin peptide analogue
GB2475422B (en) Spray discharge assembly
GB0913775D0 (en) Multispecific peptides
IL216619A0 (en) Recombinant production of peptides
EP2431464A4 (fr) Aptamere reconnaissant un peptide
EP2480578A4 (fr) Modification de polypeptide
EP2270141A4 (fr) Peptide partiel de la lacritine
EP2478010A4 (fr) Peptide partiel de lacritine
ZA201108446B (en) FViII-DERIVED PEPTIDES
HK1140909A2 (en) Show off
ZA201203722B (en) Peptide
IL222355A0 (en) Uses of natriuretic peptide constructs
TWM389844U (en) Gun
EP2437858A4 (fr) Ancre
AU4021P (en) Moonbi Glycine max
GB0911790D0 (en) Peptides
IL214496A0 (en) Short b-defensin-derived peptides
GB0901927D0 (en) Peptide for IL10 production
AU2009312V (en) Talgai Glycine max
PT2430214T (pt) Ativação de cátodo
GB0909551D0 (en) Tideway anchor improvement
GB0907672D0 (en) Reflux spray

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111220

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1168279

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20130306

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/12 20060101ALI20130228BHEP

Ipc: A61K 38/00 20060101ALI20130228BHEP

Ipc: A61P 19/00 20060101ALI20130228BHEP

Ipc: C07K 14/00 20060101ALI20130228BHEP

Ipc: C12P 21/06 20060101ALI20130228BHEP

Ipc: C12N 1/21 20060101ALI20130228BHEP

Ipc: A61P 13/12 20060101ALI20130228BHEP

Ipc: C07K 14/58 20060101ALI20130228BHEP

Ipc: A61K 47/48 20060101ALI20130228BHEP

Ipc: A61K 38/16 20060101AFI20130228BHEP

Ipc: A61K 49/00 20060101ALI20130228BHEP

Ipc: G01N 33/53 20060101ALI20130228BHEP

Ipc: A61K 38/10 20060101ALI20130228BHEP

Ipc: C12Q 1/42 20060101ALI20130228BHEP

Ipc: C07K 7/00 20060101ALI20130228BHEP

Ipc: A61P 9/00 20060101ALI20130228BHEP

Ipc: G01N 33/68 20060101ALI20130228BHEP

17Q First examination report despatched

Effective date: 20140227

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160316

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

INTG Intention to grant announced

Effective date: 20160715

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 834022

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161015

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010036978

Country of ref document: DE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2432489

Country of ref document: PT

Date of ref document: 20161207

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20161128

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20161739

Country of ref document: HR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20170109

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20161739

Country of ref document: HR

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20161005

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E013131

Country of ref document: EE

Effective date: 20161221

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2608457

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20170411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170205

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010036978

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1168279

Country of ref document: HK

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170105

26N No opposition filed

Effective date: 20170706

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E032582

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170520

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20161739

Country of ref document: HR

Payment date: 20190506

Year of fee payment: 10

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 834022

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161005

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20161739

Country of ref document: HR

Payment date: 20200507

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161005

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602010036978

Country of ref document: DE

Representative=s name: D YOUNG & CO LLP, DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20161739

Country of ref document: HR

Payment date: 20210505

Year of fee payment: 12

REG Reference to a national code

Ref country code: FI

Ref legal event code: SPCF

Spc suppl protection certif: C20220003

REG Reference to a national code

Ref country code: FR

Ref legal event code: CP

Free format text: PRODUCT NAME: VOSORITIDE; REGISTRATION NO/DATE: EU/1/21/1577 20210901

Spc suppl protection certif: 22C1004

Filing date: 20220128

Extension date: 20350519

Ref country code: FR

Ref legal event code: CP

Free format text: PRODUCT NAME: VOSORITIDE; REGISTRATION NO/DATE: EU/1/21/1577 20210901

Spc suppl protection certif: 22C1004

Filing date: 20220128

REG Reference to a national code

Ref country code: LU

Ref legal event code: SPCF

Free format text: PRODUCT NAME: VOSORITIDE SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/21/1577 20210901

Spc suppl protection certif: LUC00248

Filing date: 20220124

Expiry date: 20300520

Extension date: 20350520

REG Reference to a national code

Ref country code: GB

Ref legal event code: CTFF

Free format text: PRODUCT NAME: VOSORITIDE IN ALL FORMS PROTECTED BY THE BASIC PATENT; REGISTERED: UK EU/1/21/1577(FOR NI) 20210826

Spc suppl protection certif: SPC/GB22/003

Filing date: 20220111

REG Reference to a national code

Ref country code: NO

Ref legal event code: SPCF

Free format text: PRODUCT NAME: VOSORITIDE IN ALL FORMS PROTECTED BY THE BASIC PATENT; REG. NO/DATE: EU/1/21/1577 20210907

Spc suppl protection certif: 2022003

Filing date: 20220201

REG Reference to a national code

Ref country code: SE

Ref legal event code: SPCF

Free format text: PRODUCT NAME: VOSORITIDE IN ALL FORMS PROTECTED BY THE BASIC PATENT; REG. NO/DATE: EU/1/21/1577 20210921

Spc suppl protection certif: 2290005-4

Ref country code: EE

Ref legal event code: AA1Y

Ref document number: E013131

Country of ref document: EE

Free format text: PRODUCT NAME: VOSORITIID;REG NO/DATE: EU/1/21/1577 01.09.2021

Spc suppl protection certif: C20220003

Filing date: 20220117

REG Reference to a national code

Ref country code: DE

Ref legal event code: R065

Ref document number: 602010036978

Country of ref document: DE

Free format text: PRODUCT NAME: VOSORITID IN ALLEN DURCH DAS GRUNDPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/21/1577 20210826

Spc suppl protection certif: 122022000008

Filing date: 20220208

Expiry date: 20300521

Ref country code: NL

Ref legal event code: SPCF

Free format text: PRODUCT NAME: VOSORITIDE IN IEDERE VORM ZOALS BESCHERMD DOOR HET BASISOCTROOI; REGISTRATION NO/DATE: EU/1/21/1577 20210901

Spc suppl protection certif: 301162

Filing date: 20220214

Expiry date: 20300519

Extension date: 20350519

Ref country code: IE

Ref legal event code: SPCF

Free format text: PRODUCT NAME: VOSORITIDE IN ALL FORMS PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/21/1577 20210901

Spc suppl protection certif: 2022/005

Filing date: 20220117

REG Reference to a national code

Ref country code: BE

Ref legal event code: SPCF

Free format text: PRODUCT NAME: VOSORITIDE SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; AUTHORISATION NUMBER AND DATE: EU/1/21/1577 20210901

Spc suppl protection certif: 2022C/503

Filing date: 20220127

Expiry date: 20300520

Extension date: 20350520

REG Reference to a national code

Ref country code: DK

Ref legal event code: CTFF

Free format text: PRODUCT NAME: VOSORITIDE IN ALL FORMS; REG. NO/DATE: EU/1/21/1577 20210901

Spc suppl protection certif: CA 2022 00004

Filing date: 20220203

Expiry date: 20300520

Extension date: 20350520

REG Reference to a national code

Ref country code: AT

Ref legal event code: SPCF

Ref document number: 834022

Country of ref document: AT

Kind code of ref document: T

Free format text: PRODUCT NAME: VORSORITID, IN ALLEN DURCH DAS GRUNDPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/21/1577 (MITTEILUNG) 20210901

Spc suppl protection certif: 1/2022

Filing date: 20220118

Effective date: 20220315

REG Reference to a national code

Ref country code: ES

Ref legal event code: SPCF

Free format text: PRODUCT NAME: VOSORITIDE EN TODAS LAS FORMAS PROTEGIDAS POR LA PATENTE BASE; NATIONAL AUTHORISATION NUMBER: EU/1/21/1577; DATE OF AUTHORISATION: 20210826; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1577; DATE OF FIRST AUTHORISATION IN EEA: 20210826

Spc suppl protection certif: C202230004

Effective date: 20220128

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG1Y

Ref document number: E013131

Country of ref document: EE

Free format text: PRODUCT NAME: VOSORITIID;REG NO/DATE: EU/1/21/1577 01.09.2021

Spc suppl protection certif: C20220003 00351

Filing date: 20220117

Extension date: 20350520

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20161739

Country of ref document: HR

Payment date: 20220516

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: CT

Free format text: PRODUCT NAME: VOSORITIDE; REGISTRATION NO/DATE: EU/1/21/1577 20210901

Spc suppl protection certif: 22C1004

Filing date: 20220128

Extension date: 20350519

REG Reference to a national code

Ref country code: SE

Ref legal event code: SPCG

Free format text: PRODUCT NAME: VOSORITIDE; REG. NO/DATE: EU/1/21/1577 20210921

Spc suppl protection certif: 2290005-4

Expiry date: 20300521

Extension date: 20350520

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20161739

Country of ref document: HR

Payment date: 20230511

Year of fee payment: 14

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230523

REG Reference to a national code

Ref country code: HU

Ref legal event code: FG4S

Ref document number: E032582

Country of ref document: HU

Spc suppl protection certif: S2200004

Filing date: 20220120

REG Reference to a national code

Ref country code: ES

Ref legal event code: SPCG

Free format text: PRODUCT NAME: VOSORITIDE; NATIONAL AUTHORISATION NUMBER: EU/1/21/1577; DATE OF AUTHORISATION: 20210826; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1577; DATE OF FIRST AUTHORISATION IN EEA: 20210826

Spc suppl protection certif: C202230004

Extension date: 20350520

Effective date: 20230718

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20240418

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20240418

Year of fee payment: 15

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20161739

Country of ref document: HR

Payment date: 20240425

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20240419

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240419

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240418

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20240418

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20240419

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240602

Year of fee payment: 15

Ref country code: HR

Payment date: 20240425

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240603

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20240423

Year of fee payment: 15

Ref country code: AT

Payment date: 20240419

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NO

Payment date: 20240419

Year of fee payment: 15

Ref country code: IT

Payment date: 20240418

Year of fee payment: 15

Ref country code: FR

Payment date: 20240418

Year of fee payment: 15

Ref country code: FI

Payment date: 20240418

Year of fee payment: 15

Ref country code: EE

Payment date: 20240418

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20240422

Year of fee payment: 15

Ref country code: PT

Payment date: 20240423

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20240429

Year of fee payment: 15

Ref country code: SE

Payment date: 20240418

Year of fee payment: 15

Ref country code: HU

Payment date: 20240509

Year of fee payment: 15

Ref country code: BE

Payment date: 20240418

Year of fee payment: 15

REG Reference to a national code

Ref country code: GB

Ref legal event code: CTFG

Free format text: PRODUCT NAME: VOSORITIDE; REGISTERED: UK EU/1/21/1577(FOR NI) 20210826

Spc suppl protection certif: SPC/GB22/003

Filing date: 20220111

Extension date: 20350519

Effective date: 20240823